On July 24, Is-haq Malik, MD and Max Petersen, MD, PhD had their research titled “Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy,” published in “Obesity Society.”
The purpose of the study was to assess newly approved medications for treating obesity. “Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrated much greater weight loss.” This aided in development of an approach offering potential: “poly-agonists that combine GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide and glucagon receptor agonism.”
They state that poly-agonists offer theraputic efficacy that will likely alter the treatment paradigm for obesity. The use of medications for obesity and for other chronic diseases, “will likely require lifelong treatment, which makes it important to analyze the long-term efficacy, safety, and economic implications of chronic pharmacotherapy.”